TORONTO, ON – November 14, 2019 – CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting with investors at Piper Jaffray’s 31st Annual Healthcare Conference on December 3-5, 2019 in New York City.  CB2 Insights will join nearly 300 public and private companies in the biotechnology, specialty pharmaceutical, drug discovery and medical technology space.

CB2 Insights is one of the leading global voices in the move to mainstream medical cannabis into traditional healthcare.  The Company does so by leveraging its multi-state, US clinical operations, its proprietary data collection technology and contract research organization (CRO) services.  Managing full-service clinical operations and research services, CB2 has amassed ongoing patient data of over 100,000 unique patients annually who are seeking medical cannabis as an alternative or complement to their traditional treatment regimen.  CB2 Insights assists Licensed Producers, Multi-State Operators (MSOs), regulatory bodies and research agencies to assess the full safety and efficacy of cannabinoid therapy.

“For years, medical cannabis has existed as a fringe, alternative therapy, but we are now seeing a convergence of traditional drug development processes with increasing positive patient and government sentiment across the globe,” said Prad Sekar, CEO, CB2 Insights.  “Our work in the US, the UK, Colombia and in Canada are all proving that traditional healthcare is ready to take on cannabinoid-based medicines and our invitation to Piper Jaffray’s Healthcare Conference further solidifies that evolution.”

The panel discussion will be on Tuesday, December 3 at 2:00 pm EST. As part of the panel, “Understanding the Efficacy and Pharmacokinetics of Cannabis,” Mr. Sekar will discuss how Real-World Data (RWD) and Real-World Evidence (RWE) will be the key in accelerating the shift of cannabis-based medicine into traditional healthcare. With Real-World Data, we can move beyond traditional clinical trials and start collecting insightful data at the point-of-care.

Skylight Health

Author Skylight Health

More posts by Skylight Health

Leave a Reply